Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C1-INH add-on therapy for refractory antibody-mediated rejection after kidney transplant
NL-OMON50633Phase 3Active, not recruiting
- Sponsor
- CSL Behring
- Start
- Jun 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of c1-esterase inhibitor in Antibody-mediated kidney allograft rejection (AMR) and kidney allograft rejection (4 arms), sponsored by CSL Behring. Started Jun 2018; status: active, not recruiting.
02
Drugs
c1-esterase inhibitor
03
Conditions
Antibody-mediated kidney allograft rejection (AMR)kidney allograft rejection
Beyond the preview
Go deeper on NL-OMON50633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50633.